Screening Tests and Other Steps for Zolgensma’s Use – Here’s Why They’re Necessary
Monitoring liver function and immune reactions, being alert to signs of a respiratory infection, and making sure that a child’s…
Articles by José Lopes, PhD
Ontario SMA Patients Granted Wider Access to Spinraza
Ontario has expanded publicly funded access to Spinraza (nusinersen) to cover spinal muscular atrophy (SMA) types 2 and…
SMA Candidate SRK-015 Shows Promise in Healthy Volunteers; Trial Ongoing
Top-line results from a Phase 1 trial showed that SRK-015 had a positive safety profile and durable effects in…
Expert Views on Likely Future Work into Zolgensma, Gene Therapies and Other SMA Treatments
[Editor’s note: This is the sixth and final entry in a series of articles on Zolgensma and treatments for SMA,…
Zolgensma’s Price and Its ‘Cure One, Cure Many’ Potential: An Interview with Researchers
[Editor’s note: This is the fourth in a series of articles on Zolgensma and treatments for SMA, the issues they…
For SMA Types 1-3, Options to Zolgensma Exist and More May Be on Way
[Editor’s note: This is the third in a series of articles on Zolgensma and treatments for SMA, the issues they…
Zolgensma Can Best Help Babies Treated Early – But Older Patients May Also Benefit, Experts Say
[Editor’s note: This is the second in a series of articles on Zolgensma and treatments for SMA, the issues they…
Zolgensma Has Potential to ‘Change Whole Landscape of SMA,’ Experts Say
[Editor’s note: This is the first in a series of articles on Zolgensma and treatments for SMA, the issues they…
IV vs. IT Delivery: Zolgensma’s Different Treatment Routes for SMA
The gene therapy Zolgensma (onasemnogene abeparvovec-xioi) has been newly approved to treat patients with spinal muscular atrophy (SMA)…
Zolgensma ‘Transformative’ for SMA and Gene Therapies to Come, Jerry Mendell Says in Interview
From its very first clinical trial — using a dose widely frowned upon — Zolgensma has had a “transformative” impact on…